BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM ESTLeerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.
Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More
Streetinsider.com's Hot Lunchtime Reads 11/23: (JUNO) (AMZN) (AXON) (LLY)
November 23, 2016 12:30 PM ESTThe following is a list of notable articles to help get you through the lunch hour:Amazon.com (AMZN) Said Planning New Video Chat Service Following Recent Acquisition ->... More
Eli Lilly & Co. (LLY) 30-day call option implied volatility is at 66, compared to a one month ago level of 24.
November 23, 2016 11:47 AM ESTEli Lilly & Co. (NYSE: LLY) 30-day call option implied volatility is at 66, compared to a one month ago level of 24.
... MoreLilly's (LLY) Solanezumab Phase 3 Miss is Credit-Negative Event - Moody's
November 23, 2016 11:41 AM ESTMoody's Investor Service commented that Eli Lilly and Company's (NYSE: LLY) announcement that its experimental Alzheimer's disease drug solanezumab did not meet the endpoint in a Phase III trial is credit negative. There is no effect on Lilly's A2 rating or stable rating outlook.
... MoreOptions with increasing volume: BYD LLY VRX CELG URBN CTRP HPQ DE GME MU
November 23, 2016 9:51 AM ESTOptions with increasing volume: BYD LLY VRX CELG URBN CTRP HPQ DE GME MU
... MoreNeurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease
November 23, 2016 9:50 AM ESTNeurotrope, Inc. (OTC: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, issued a statement on Eli Lilly's (NYSE: LLY) experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical trial, solanezumab failed to improve cognition of patients with mild Alzheimer's disease.
Dr. Daniel Alkon,... More
Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
November 23, 2016 9:24 AM ESTToday's Pre-Open Stock Movers
Medigus Ltd. (NASDAQ: MDGS) 41.6% HIGHER; announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement.
Euroseas Ltd. (Nasdaq:... More
Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink
November 23, 2016 7:57 AM ESTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More
Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola Failure
November 23, 2016 7:50 AM ESTAxovant Sciences (NYSE: AXON) is down 17% in pre-open trade after Eli Lilly & Co. (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreEli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM ESTLeerink Partners analyst Seamus Fernandez weighed in on Eli Lilly & Co. (NYSE: LLY) after sola failed, saying this makes the future of the company's AD portfolio uncertain.
Fernandez commeted, "This morning LLY announced that its EXPEDITION 3 trial of solanezumab (sola) did NOT... More
Dow, S&P 500 set record high closes ahead of holiday
November 23, 2016 7:33 AM ESTBy Caroline Valetkevitch
NEW YORK (Reuters) - The Dow and the S&P 500 eked out record high closes on Wednesday ahead of the Thanksgiving holiday, helped by gains in industrial stocks, though losses in technology shares limited the advance and weighed on the Nasdaq.
Caterpillar (NYSE: CAT) rose 2.7 percent and hit the highest in about two years, while Deere (NYSE: DE) jumped 11 percent to a record high close after the farm equipment maker reported a much smaller-than-expected decline in profit.
Industrial... More
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM ESTEli Lilly & Co. (NYSE: LLY) CEO John Lechleite says there's no concern about the company's dividend, according to CNBC.
David A. Ricks. Senior Vice President and President, Lilly Bio-Medicines, also added that investors want the company to continue exploring solutions for Alzheimer's disease.
... MoreEli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM ESTEli Lilly & Co. (NYSE: LLY) falls 11% after the company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreBiogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM ESTBiogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreEli Lilly & Co. (LLY) volatility elevated into Alzheimer's data
November 23, 2016 6:51 AM ESTEli Lilly & Co. (NYSE: LLY) November weekly call option implied volatility is at 78, December is at 70, January is at 49; compared to its 52-week range of 14 to 64 into the solanezumab data for Alzheimer's.
... MoreEli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary Endpoint
November 23, 2016 6:45 AM ESTEli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale).
While the study results, including many secondary clinical endpoints, directionally favored solanezumab, the magnitudes of treatment differences were small.... More